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Abstract 
Caffeine was administered to male Wistar albino rats for two weeks at three concentrations, namely 0.1, 0.2 and 0.3%, and hepatic 
cytochrome P450-dependent mixed-function xidases determined. Caffeine administration gave rise to a marked, dose-dependent i crease 
in the O-deethylation f ethoxyresorufin a d, to a lesser extent, in the O-depentylation f pentoxyresorufin. Erythromycin N-demethylase, 
p-nitrophenol hydroxylase and lauric acid hydroxylase activities, as well as total cytochrome P450 content were unaffected by this 
treatment. Immunoblot analysis revealed that caffeine gave rise to a dose-dependent i crease in the hepatic CYPIA2, and at the highest 
dose only, CYP2B apoprotein levels. Apoprotein levels of CYP3A and CYP2E1 were not modulated by the treatment with caffeine at all 
dose levels studied. Caffeine could not displace [3H]TCDD from the rat hepatic cytosolic Ah receptor. Computer analysis showed that 
caffeine is essentially a planar molecule with an area/depth 2 ratio 4.8, characteristic of CYPlA substrates/inducers. Molecular 
modelling revealed that the caffeine molecule could orientate itself within the putative CYPIA2 active site so as to facilitate 
demethylation of the N-I, N-3 and N-7 positions. However, at physiological pH, the N-9 nitrogen atom is likely to be partially 
protonated, allowing it to participate in an electrostatic interaction with the negatively-charged glutamate 318-residue, favouring N-3 
demethylation, the major pathway of metabolism in both humans and animals. In conclusion caffeine, being essentially planar, is an 
inducer of CYPIA2 in rat liver. 
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I. Introduction 
Strong epidemiological evidence has established un- 
equivocally that dietary habits play an important role in 
both the initiation and progression of disease. Numerous 
carcinogens have been identified in food, being either 
inherent in food, contaminants, or formed during the cook- 
ing process [1]. Conversely, many chemicals present in 
food display marked antimutagenic/anticarcinogenic prop- 
erties and can afford protection against hese carcinogens. 
An additional mechanism through which diet can influence 
carcinogenesis is by modulating the production of reactive 
intermediates, the ultimate carcinogens, which interact with 
DNA to initiate the complex process leading to tumourige- 
nesis [2]. Indeed, modification of the protein, lipid, carbo- 
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hydrate, vitamin and mineral content, as well as a reduc- 
tion in calorific content have been associated with marked 
changes in the incidence of spontaneous and chemically- 
induced cancers in various animal models [3]. However, 
what is often ignored is that diet also contains an array of 
anutrients which have the potential to perturb the metabolic 
fate of xenobiotics, including chemical carcinogens. 
One of the most extensively consumed dietary con- 
stituents is caffeine (l,3,7-trimethylxanthine), a constituent 
of coffee, a popular beverage world-wide. It is also present 
in many other drinks, including tea, cocoa and cola drinks. 
An average cup of coffee contains about 100 mg so that 
the daily intake of caffeine may be as high as 1 g/day.  
Moreover, it is found in many medications, particularly 
analgesics. Caffeine undergoes extensive metabolism catal- 
ysed by the cytochrome P450-dependent mixed-function 
oxidases, the major metabolic products being demethylated 
and hydroxylated metabolites [4-8]. Epidemiological stud- 
ies have associated coffee consumption with increased 
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cancer isk at a number of sites including the breast, colon, 
ovaries, pancreas and urinary tract [9-11], although other 
workers failed to establish similar relationships [ 12,13]. In 
various animal models caffeine was shown to modulate the 
carcinogenicity of chemicals, potentiating or suppressing 
their effects [14]. In addition, caffeine has displayed posi- 
tive genotoxic effects in a limited number of short-term 
tests [15,16]. However, the precise mechanism through 
which coffee influences chemical carcinogenesis remains 
unclear. It is conceivable that caffeine could exert its 
effects by modifying the generation of ultimate carcino- 
gens, as a result of changes in the activities of the enzyme 
systems catalysing the activation and detoxication of 
chemical carcinogens. Indeed, previous studies have 
demonstrated that caffeine induces the hepatic mixed-func- 
tion oxidases in animals [17,18]. However, at that time it 
was believed that cytochromes P450 comprised, at most, 
two proteins and, consequently, the effect of caffeine on 
individual, inducible cytochrome P450 isoforms has not 
been studied in detail. 
The purpose of the present study is to investigate the 
effect of orally-administered caffeine on the hepatic, xeno- 
biotic-metabolising, inducible cytochrome P450 proteins in 
the rat. This will be achieved using diagnostic probes, 
supported by immunoblot analysis employing specific 
polyclonal antibodies. 
2. Materials and methods 
Resorufin and alkoxyresorufins (Molecular Probes, Eu- 
gene, OR, USA), [14C]lauric acid (Amersham Interna- 
tional, Amersham, UK), tetrachloro-dibenzo-p-dioxin 
(TCDD) (Chemsyn Science Laboratories, Kansas, USA), 
tetrachloro-dibenzofuran (TCDF) (Promochem, St. Albans, 
Herts., UK), p-nitrophenol, erythromycin, lauric acid, per- 
oxidase-labelled donkey anti-sheep IgG and all cofactors 
(Sigma, Poole, Dorset, UK) were all purchased. Purifica- 
tion and production of antibodies to rat CYP1A1, recognis- 
ing both CYP1A1 and CYP1A2, have already been de- 
Fig. 1. Induction of hepatic CYPIA apoproteins by caffeine treatment of 
rats. Solubilised hepatic microsomal samples were resolved by 10% 
(w/v)  SDS-PAGE and transferred electrophoretically to nitrocellulose. 
The immunoblot was carried out with sheep anti-CYP1Al (diluted 1:10 
000) followed by peroxidase-labelled donkey anti-sheep IgG (diluted 1:2 
500) All lanes were loaded with 40 /xg of protein. C, control; F1, 0.1% 
caffeine; F2, 0.2% caffeine; F3, 0.3% caffeine; Ar, Aroclor 1254-induced 
microsomes. 
scribed [19]. Polyclonal antibodies to CYP2B and CYP3A, 
and to CYP2E1 were generous gifts from C.R. Wolf 
(Ninewells Hospital and Medical School, Dundee, UK) 
and D.R. Koop (Oregon Health Sciences University, OR, 
USA) respectively. 
Male Wistar albino rats (150-190 g) were obtained 
from the Experimental Biology Unit, University of Surrey 
and were randomly divided into four groups comprising 
five animals each. One group served as controls and the 
others were given caffeine in their drinking water at three 
concentrations, 0.1, 0.5 and 1.0% (w/v). However, as the 
animals in the latter two groups started to lose weight, on 
the sixth day following commencement of the study the 
concentrations were reduced to 0.2 and 0.3% respectively. 
Animals were exposed to the caffeine for a total of two 
weeks, after which they were killed by cervical disloca- 
tion, their livers were excised, and microsomai and cytoso- 
lic fractions prepared as previously described [20]. The 
following assays were performed on isolated microsomes: 
the dealkylations of ethoxyresorufin [21] and pentoxyre- 
sorufin [22], p-nitrophenol hydroxylase [23], erythromycin 
N-demethylase [24], lauric acid hydroxylase measuring the 
Table 1 
Effect of caffeine administration  hepatic cytochrome P450-dependent mixed-function oxidases in the rat 
Parameter Control Caffeine 
0.1% (w/v)  0.2% (w/v)  0.3% (w/v)  
Ethoxyresorufin O-deethylase (pmol/min per mg protein) 
Pentoxyresorufin O-depentylase (pmol/min per mg protein) 
p-Nitrophenol hydroxylase (nmol/min per mg protein) 
Erythromycin N-demethylase (nmol/min per mg protein) 
Lauric acid hydroxylase (nmol/min per mg protein) 
Total cytochrome P450 (nmol/mg protein) 
Microsomal protein (mg/g liver) 
100_+ 15 674_+ 150 * * * ll01 _ 176 * * * 1170±525 * * 
44-+_ 10 203 _+ 85 * 271 _+ 94 * * 268 + 146 * 
1.204-0.12 1.28 + 0.13 1.30_+0.13 1.28_+0.08 
3.50 _+ 0.22 3.28 + 0.25 3.63 _+ 0.52 3.67 _+ 0.20 
1.57+0.43 1.70_+0.18 1.32+0.33 1.63_+0.43 
0.62+0.12 0.71 +0.12 0.81 +0.31 0.66+0.09 
20-+ 1 22-+3 27_+3 ** 23+_4 
* P<0.05 ,  * * P<0.01,  ** * P<0.001.  
Rats were maintained on caffeine in their drinking water for two weeks. All assays were performed using isolated microsomes. Results are presented as 
means + S.D. for 5 animals. 
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Fig. 2. CYP2B apoprotein levels in the liver of caffeine-treated rats. Solubilised hepatic microsomal samples were resolved by 10% (w/v) SDS-PAGE and 
transferred electrophoretically to nitrocellulose. The immunoblot was carried out with rabbit anti-CYP2B (diluted 1:2000) followed by peroxidase-labelled 
goat anti-rabbit IgG (diluted 1:2000). All lanes were loaded with 30 /xg of protein. C, control; FI, 0.1% caffeine; F2, 0.2% caffeine; F3, 0.3% caffeine; 
PB, phenobarbital-induced microsomes. 
combined products of 11-and 12-hydroxylation [25], total 
cytochrome P450 [26] and protein [27]. 
lmmunoblot analysis of solubilised microsomes follow- 
ing resolution by electrophoresis [28] was performed as 
described by Towbin et al. [29]. To serve as positive 
controls in the immunological studies, rats were treated 
with a single intraperitoneal dose of Aroclor 1254 (500 
mg/kg) and were killed on the 5th day following adminis- 
tration. Additional animals were treated with single intra- 
peritoneal administrations of phenobarbitone (80 mg/kg), 
or dexamethasone (100 mg/kg) by gastric gavage, for 3 
days, all animals being killed 24 h after the last administra- 
tion. Finally, a further group of animals were exposed to 
isoniazid (0.1% w/v  in drinking water for 7 days). 
Displacement of [ 3 H]TCDD from the rat hepatic ytoso- 
lic Ah-receptor was determined by the hydroxyapatite 
method of Gasiewicz and Neal [30]. 
Molecular modelling was carried out using the Sybyl 
software system running on an Evans and Sutherland 
ESV30 unix workstation. A 3-dimensional molecular model 
Fig. 3. Effect of treatment with caffeine on rat hepatic CYP2EI and CYP3A apoprotein levels. Solubilised hepatic microsomes were resolved by 10% 
(w/v) SDS-PAGE and transferred electrophoretically to nitrocellulose. (A) The immunoblot was carried out using sheep anti-CYP2El (diluted 1:5000) 
followed by peroxidase-labelled donkey anti-sheep IgG (diluted 1:2000). (B) The immunoblot was carried out with rabbit anti-CYP3Al (diluted 1:2000) 
followed by peroxidase-labelled goat anti-rabbit IgG (diluted 1:2000). All lanes were labelled with 40 /xg protein. C, control, FI, 0.1% caffeine; F2, 0.2% 
caffeine; F3, 0.3% caffeine; I, isoniazid-treated microsomes; D, dexamethasone-treated microsomes. 
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Table 2 
Binding of caffeine to the Ah receptor 
Displacing ligand and concentration TCDD-binding to the 
Ah receptor (% of control) 
Caffeine 10-6M 105 +6 
Caffeine 10-4M 107 +4 
Chrysene (10 .7 M) 17 +4 
6-Aminochrysene (10-8 M) 51 +7 
The assay was carried out using [3H]TCDD as the ligand (0.3 nM) and a 
cytosolic protein concentration f 2 mg/ml. Non-specific binding was 
determined from incubations ofthe ligand with TCDF (200 nM). Results 
are presented asmean _ S.D. of triplicates. 
of the CYP1A2 protein was used [31], constructed from 
the recently-published, crystal structure of the prokaryotic 
form, CYP 102 [32]. 
Statistical analysis was carried out using the Student's 
t-test. 
3. Results 
Exposure of rats to caffeine in their drinking water for 
two weeks gave rise to a statistically significant and 
dose-dependent i crease in the O-deethylation of ethoxyre- 
sorufin and, to a lesser extent, in the O-depentylation of 
pentoxyresorufin (Table 1). The same treatment had no 
effect on the erythromycin N-demethylase, p-nitrophenol 
hydroxylase and lauric acid hydroxylase activities. Simi- 
larly, total cytochrome P450 levels in the liver were unaf- 
fected. Immunoblot analysis using antibodies to CYPIA1 
revealed that the treatment with caffeine caused a dose-de- 
pendent increase in the hepatic apoprotein levels of 
CYP1A2 (Fig. 1). CYPIA1 was detectable neither in the 
control nor in the caffeine-treated hepatic microsomes. 
Probing with antibodies to CYP2B demonstrated an in- 
crease in CYP2B apoprotein levels, but only at the highest 
dose (Fig. 2). Treatment with caffeine did not influence the 
CYP2E1 and CYP3A apoprotein levels (Fig. 3). 
Caffeine, at a maximum concentration of 10 -4 M, 
failed to displace [3H]TCDD from the cytosolic receptor of 
untreated rats, whereas chrysene and 6-methylchrysene, as 
expected [33], gave rise to a displacement of about 80 and 
50% respectively (Table 2). 
The structural characteristics of caffeine were: length 
10.0 ,~, width 8.5 A and depth 4.2 ,& giving rise to an 
area/depth 2 ratio of 4.8. The distances of the N-methyl 
hydrogens of caffeine from the haem Fe = O group were 
2.849 A for the 7-methyl, 3.415 ,~ for the 3-methyl and 
3.746 A for the l-methyl. Its AE [E(HOMO) E(LEMO)] 
value is 13.5 eV. Fig. 4 shows the orientation of caffeine 
within the putative site of CYP1A2 for N-7 demethylation, 
where this methyl group is positioned close to the pro- 
posed active oxygen species bound to the haem iron. 
~xlSI ~7 
t 
87 
Fig. 4. The putative rat hepatic CYP1A2 active site with caffeine docked. 
Caffeine is orientated for N-7 demethylation, with the methyl group 
positioned in close proximity to the proposed active oxygen species 
bound to the haem iron. 
4. Discussion 
Caffeine is currently enjoying extensive use as a spe- 
cific in vivo probe for CYP1A2 activity in both animals 
and man. This is achieved by measuring the urinary excre- 
tion of caffeine metabolites or the exhalation of CO 2 
[34,35]. Recent studies employing genetically-expressed 
cytochrome P450 proteins revealed that the major catalyst 
of caffeine metabolism in rat and man is CYP1A2 [36,37]. 
In early studies caffeine has been shown to induce the 
cytochrome P450-dependent mixed-function oxidases in a 
number of animal species including the rat [38-40], but the 
effect of caffeine on specific cytochrome P450 isoforms 
has not been investigated and is addressed in the present 
study. Caffeine gave rise to a dose-dependent i crease in 
the O-deethylation of ethoxyresorufin, a specific probe for 
the CYP1A subfamily [41], and this was confirmed im- 
munologically in Western blots. Moreover, the latter stud- 
ies revealed that caffeine selectively induced the CYPIA2 
isoform. An increase was also evident in the O-dealkyla- 
tion of pentoxyresorufin, a diagnostic probe for the CYP2B 
subfamily [22]; however, many CYP1A inducers, to some 
extent, also enhance this activity [42] but at the highest 
dose only (0.3% w/v)  an increase in CYP2B apoprotein 
levels was clearly evident, indicating induction of this 
isoform. The treatment with caffeine had no effect on 
p-nitrophenoi hydroxylase, a probe for CYP2EI [23], ery- 
E.O. A yalogu et al. / Biochimica et Biophysica Acta 1272 (1995) 89-94 93 
thromycin N-demethylase, a probe for CYP3A [24] and 
lauric acid, a probe for CYP4A1 [43]. Immunological 
analysis confirmed the lack of induction of CYP2EI and 
CYP3A. Thus, at low doses caffeine selectively induces 
the CYP1A2 isoform, i.e., the major catalyst of its 
metabolism. Bearing in mind that caffeine is an essentially 
planar molecule, with an area/depth 2 of 4.8, it is not 
surprising that it is a selective substrate/inducer of the 
CYP1A2 protein [44,45]. All three possible orientations of 
the caffeine molecule, which lead to N-demethylation, fit
favourably within the putative substrate site of CYP1A2, 
and can each participate in hydrogen bonding with two 
hydrogen-bond donor amino acids (Thr 88 and Asn 82), 
together with aromatic 7r-Tr stacking interactions with two 
aromatic amino acid residues (Phe 181 and Tyr 437), as 
illustrated in Fig. 2, which adopts the CYPI02 numbering 
system. Although each of these orientations appear 
favourable, the N-7 methyl group was closer to the haem- 
bound oxygen, suggesting that this may be the major site 
of demethylation. In contrast o these findings, however, 
studies using rat and human CYP1A2 expressed by geneti- 
cally engineered cell lines showed that demethylation at
the N-3 position is clearly favoured [36,37]. In recent 
theoretical studies using ab initio molecular orbital meth- 
ods [46], it was shown that the N-9 nitrogen atom of 
caffeine is associated with a high negative electrostatic 
potential energy, suggesting that, at physiological pH, it 
may be partially protonated, as is theophylline, a struc- 
turally related compound. If such a situation exists when 
caffeine interacts with the CYP1A2 substrate site, then an 
electrostatic nteraction could occur with the negatively- 
charged glutamate-318 residue, adjacent o the invariant 
threonine associated with the oxygenation mechanism. Ori- 
entation of the caffeine molecule for the N-3 demethyl- 
ation would be favoured by this ion-pairing interaction, 
whereas for N-7 demethylation, the N-9 nitrogen atom 
points to the opposite direction. Thus, it is likely that the 
glutamate-318 residue cooperatively assists the binding 
and orientation of caffeine within the active site of 
CYPIA2, in addition to the previously described hydro- 
gen-bonding. 
Induction of the CYPIA subfamily is mediated by a 
cytosolic protein, the Ah receptor, to which the inducer 
binds and the complex formed translocates into the nucleus 
where it interacts with specific sites on the DNA, activat- 
ing a number of genes, including those coding for the 
CYPIA proteins [47]. Indeed, good correlations have been 
established between inductive potency and affinity for the 
receptor [48]. Caffeine, despite being a good CYP1A 
inducer, failed to interact with the Ah receptor, as deter- 
mined using the hydroxyapatite method. Such an observa- 
tion has also been reported for other compounds [49]. It is 
likely that the caffeine-induced increase in CYP1A2 is not 
the result of transcriptional ctivation but may involve 
other molecular mechanisms uch as mRNA or protein 
stabilisation. Alternatively, caffeine may mediate its effect 
through interaction with other receptors related to the Ah 
receptor [50]. 
The lowest concentration employed in the present study, 
0.1% (w/v), is equivalent to a dose of approximately 80 
mg/kg per day. The daily caffeine intake of heavy coffee 
drinkers, assuming an average body weight of 60 kg, is 
about 17 mg/kg which is lower but comparable to that 
administered to the rats. It is pertinent to point out, how- 
ever, that the rat is more efficient in eliminating caffeine, 
having a half-life of 0.84 h, compared to a value of 4.19 h 
in man [51]. Consequently, for the same dose, plasma 
levels are likely to be substantially higher in man; more- 
over, in the present study caffeine was administered for the 
relatively short time of two weeks. It is reasonable to 
assume that, at least in heavy coffee drinkers, caffeine 
stimulates CYP1A2 and may contribute to the marked 
inter-individual variation in this activity [52]. 
The role of caffeine in modulating carcinogenesis, at
least as far as substrates of CYP1A2 are concerned, will 
primarily depend on the time of caffeine intake relative to 
that of the carcinogen. Prior ingestion of caffeine, giving 
rise to higher CYPIA2 activity, will stimulate the bioacti- 
vation of the carcinogen and thus potentiate its carcino- 
genicity. If, however, both chemicals are simultaneously 
administered, competitive inhibition resulting in sup- 
pressed bioactivation of the carcinogen and diminished 
carcinogenic response is likely. Even if induction does 
occur under such circumstances, following prolonged in- 
take of caffeine, the presence of caffeine at the substrate- 
binding site might render the enzyme catalytically unavail- 
able to activate the carcinogen. This, of course, will de- 
pend on their K m values and relative concentrations at the 
substrate binding site. 
Of concern to humans is the fact that perhaps the most 
frequently consumed carcinogens are the heterocyclic 
amines generated during cooking [53], which are activated 
by the CYPIA2 isoform [54]. As already discussed (vide 
supra), the relative time of ingestion is of primary impor- 
tance. It is worth pointing out that the amount of caffeine 
intake is orders of magnitude higher than that of the 
heterocyclic amines and when these are simultaneously 
consumed, caffeine is likely to afford protection. 
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